Bruton's tyrosine kinase is at the crossroads of metabolic adaptation in primary malignant human lymphocytes.
AuthorsSharif-Askari B, Doyon D, Paliouras M, Aloyz R
JournalSci Rep
PubMed ID31363127
'In this work we explored metabolic aspects of human primary leukemic lymphocytes that hold a potential impact on the treatment of Bruton tyrosine kinase (BTK)-driven diseases. Our results suggest that there is crosstalk between Bruton tyrosine kinase (BTK) signaling and bioenergetic stress responses. In primary chronic lymphocytic leukemia (CLL) lymphocytes, ... More
Ibrutinib Resistance Is Reduced by an Inhibitor of Fatty Acid Oxidation in Primary CLL Lymphocytes.
AuthorsGalicia-Vázquez G, Aloyz R
JournalFront Oncol
PubMed ID30319974
Chronic Lymphocytic Leukemia (CLL) is an incurable disease, characterized by the accumulation of malignant B-lymphocytes in the blood stream (quiescent state) and homing tissues (where they can proliferate). In CLL, the targeting of B-cell receptor signaling through a Burton's tyrosine kinase inhibitor (ibrutinib) has rendered outstanding clinical results. However, complete ... More